1. Home
  2. NKTX vs NYXH Comparison

NKTX vs NYXH Comparison

Compare NKTX & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nkarta Inc.

NKTX

Nkarta Inc.

HOLD

Current Price

$2.93

Market Cap

198.2M

Sector

Health Care

ML Signal

HOLD

Logo Nyxoah SA

NYXH

Nyxoah SA

HOLD

Current Price

$1.69

Market Cap

161.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTX
NYXH
Founded
2015
2009
Country
United States
Belgium
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
198.2M
161.9M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
NKTX
NYXH
Price
$2.93
$1.69
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
3
Target Price
$11.33
$9.33
AVG Volume (30 Days)
794.4K
308.3K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
11.88
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$213.98
Revenue Next Year
N/A
$126.25
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.70
$1.26
52 Week High
$3.72
$8.59

Technical Indicators

Market Signals
Indicator
NKTX
NYXH
Relative Strength Index (RSI) 48.54 41.51
Support Level $2.50 $1.26
Resistance Level $3.29 $3.36
Average True Range (ATR) 0.31 0.11
MACD 0.03 0.06
Stochastic Oscillator 22.91 60.00

Price Performance

Historical Comparison
NKTX
NYXH

About NKTX Nkarta Inc.

Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK-cell expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

About NYXH Nyxoah SA

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

Share on Social Networks: